CARGO Therapeutics Phase 1 clinical study in patients with relapsed or refractory large B-cell lymphoma was published in The Lancet. Exciting news for the team!
Congratulations to Stanford University School of Medicine investigators on the first peer-reviewed publication of their Phase 1 clinical study evaluating our lead candidate CD22 CAR T-cell therapy, firi-cel, in the The Lancet! These impactful findings continue to demonstrate the curative potential of firi-cel and support the study design of our currently enrolling Phase 2 program. Learn more: https://lnkd.in/dH_QQNmK #CART #celltherapy